Quanta Therapeutics
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $50M
Overview
Developing small molecule cancer therapies targeting difficult protein-protein interactions.
Oncology
Technology Platform
A structure-based drug discovery platform designed to identify and optimize small molecules that disrupt intracellular protein-protein interactions, a historically challenging class of targets.
Funding History
1Total raised:$50M
Series D$50M
Opportunities
First-in-class potential for its mechanism and the ability to address large patient populations with RAS-pathway mutations.
Risk Factors
High risk of clinical failure due to the novel mechanism and potential for rapid competitive advancements from larger pharmaceutical companies.
Competitive Landscape
Enters a crowded oncology field with direct competition from other KRAS players, requiring clear differentiation in efficacy or safety profile.